Associations of Sensory and Motor Function with Blood-Based Biomarkers of Neurodegeneration and Alzheimer's Disease in Midlife

 

With your elevated risk of Alzheimers/dementia you'll want your doctor following this carefully.  Is your doctor ensuring further studies occur?

Or is your doctor incompetently WAITING FOR SOMEONE ELSE TO SOLVE THE PROBLEM? 

Your risk of dementia, has your doctor told you of this?

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

What is your doctor's EXACT PROTOCOL TO PREVENT DEMENTIA?

The latest here:

Associations of Sensory and Motor Function with Blood-Based Biomarkers of Neurodegeneration and Alzheimer's Disease in Midlife

Author links open overlay panelAdam J.Paulsen¹

Carla R.Schubert¹Alex A.Pinto¹Richard J.Chappell²YanjunChen¹Karen J.Cruickshanks¹³Corinne D.Engelman³LuigiFerrucci⁴Laura M.Hancock⁵Sterling C.Johnson⁶⁷NataschaMerten⁸

https://doi.org/10.1016/j.neurobiolaging.2022.08.008Get rights and content

Highlights

•

Serum NfL and Tau levels increased, and Aβ₄₂/Aβ₄₀ ratio decreased over 10 years

•

Serum NfL levels correlated well with NfL levels in plasma and CSF

•

Serum NfL was higher and Aβ₄₂/Aβ₄₀ ratio lower in those with CSF or PET amyloid

•

Midlife hearing impairment associated with faster increase in NfL level over time

•

Worse midlife motor function associated with faster increase in NfL over time

Abstract

Pathological biomarkers of dementia and Alzheimer's disease (AD) change decades before clinical symptoms. Common sensory and motor changes in aging adults may be early markers of neurodegeneration. We investigated if midlife sensory and motor functions in Beaver Dam Offspring Study (BOSS) participants (N=1529) were associated with longitudinal changes in blood-based biomarkers of neurodegeneration (neurofilament light chain (NfL); total tau (TTau)) and AD (amyloid beta (Aβ)). Mixed-effects models with baseline sensory and motor function as determinants and 10-year biomarker change as outcome were used. Participants with hearing impairment and worse motor function (among women) showed faster increases in NfL level over time (0.8%/year; 0.3%/year, respectively). There were no significant associations with TTau or Aβ.

We found consistent relationships between worse baseline hearing and motor function with a faster increase in neurodegeneration, specifically serum NfL level. Future studies with longer follow-up should determine if sensory and motor changes are more reflective of general neurodegeneration than AD-specific pathology and whether sensory and motor tests may be useful screening tools for neurodegeneration risk.